Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 3, pp 295–300

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

  • W. Yeo
  • M. Boyer
  • H. C. Chung
  • S. Y. K. Ong
  • R. Lim
  • Benny Zee
  • B. Ma
  • K. C. Lam
  • F. K. F. Mo
  • E. K. W. Ng
  • R. Ho
  • S. Clarke
  • J. K. Roh
  • P. Beale
  • S. Y. Rha
  • H. C. Jeung
  • R. Soo
  • B. C. Goh
  • A. T. C. Chan
Original Article

DOI: 10.1007/s00280-006-0270-1

Cite this article as:
Yeo, W., Boyer, M., Chung, H.C. et al. Cancer Chemother Pharmacol (2007) 59: 295. doi:10.1007/s00280-006-0270-1

Abstract

Background

The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer.

Patients and methods

Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks.

Results

The median number of cycles delivered per patient was 2 (range 1–6). Two patients (9%) had ≥ 1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55–9.39).

Conclusions

Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

Keywords

IrofulvenStomach cancerFirst line chemotherapy

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • W. Yeo
    • 1
    • 2
  • M. Boyer
    • 3
  • H. C. Chung
    • 4
  • S. Y. K. Ong
    • 5
  • R. Lim
    • 6
  • Benny Zee
    • 1
    • 2
  • B. Ma
    • 1
    • 2
  • K. C. Lam
    • 1
    • 2
  • F. K. F. Mo
    • 1
    • 2
  • E. K. W. Ng
    • 1
    • 2
  • R. Ho
    • 1
    • 2
  • S. Clarke
    • 3
  • J. K. Roh
    • 4
  • P. Beale
    • 3
  • S. Y. Rha
    • 4
  • H. C. Jeung
    • 4
  • R. Soo
    • 6
  • B. C. Goh
    • 6
  • A. T. C. Chan
    • 1
  1. 1.Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong
  2. 2.Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong
  3. 3.Sydney Cancer CentreRoyal Prince Alfred HospitalSydneyAustralia
  4. 4.Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of MedicineYonsei, SeoulKorea
  5. 5.Department of Medical OncologyNational Cancer CentreSingaporeSingapore
  6. 6.Department of Haematology–OncologyNational University HospitalSingaporeSingapore